SAN FRANCISCO, CA–(Marketwired – May 19, 2017) – In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program.
Included in this article is: Sunesis Pharmaceuticals Inc.
In a May 1 research report, Wells Fargo expressed the view that SNS062, the Sunesis Pharmaceuticals Inc. drug in development for patients with chronic lymphocytic leukemia (CLL) that is resistant to Imbruvica (ibrutinib), is “a greater value driver for the stock.”
The report notes that company resources directed toward gaining approval from the European Medicines Agency for vosaroxin, which targets acute myeloid leukemia, will now be directed toward a clinical trial for SNS062.
“We see significant upside potential on novel BTK inhibitor SNS062 in the large IMBRUVICA resistance market and with potential validation by YE17,” the Wells Fargo report concludes.
In a May 10 report, Edison Investment Research states that Sunesis “will be initiating a Phase Ib/II clinical trial in Q217” for SNS062. The study is expected to read out in September 2018.
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURE:
The following companies mentioned are sponsors of Streetwise Reports: Sunesis Pharmaceuticals Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Please see the end of the article for the complete disclosures: Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug
Contact Information:
Carrie Beal Amaro
Associate Publisher
Email contact